LabCorp Extends Tender Offer for All Outstanding Shares of Orchid Cellmark Inc.

BURLINGTON, N.C. --(BUSINESS WIRE)--Dec. 1, 2011-- Laboratory Corporation of America® Holdings (NYSE: LH) today announced that LabCorp is extending until 5:00 p.m. , New York City time, on December 9, 2011 , LabCorp’s previously announced cash tender offer for all outstanding shares of the common

LabCorp Extends Tender Offer for All Outstanding Shares of Orchid Cellmark Inc.

BURLINGTON, N.C. --(BUSINESS WIRE)--Nov. 15, 2011-- Laboratory Corporation of America® Holdings (NYSE: LH) today announced that LabCorp is extending until 5:00 p.m. , New York City time, on November 30, 2011 LabCorp’s previously announced cash tender offer for all outstanding shares of the common

LabCorp Extends Tender Offer for All Outstanding Shares of Orchid Cellmark Inc.

BURLINGTON, N.C., Nov 07, 2011 (BUSINESS WIRE) -- Laboratory Corporation of America(R) Holdings (NYSE: LH) today announced that LabCorp is extending until 5:00 p.m., New York City time, on November 14, 2011 LabCorp's previously announced cash tender offer for all outstanding shares of the common

LabCorp is Scheduled to Present at the Credit Suisse 2011 Healthcare Conference

BURLINGTON, N.C., Nov 03, 2011 (BUSINESS WIRE) -- Laboratory Corporation of America (R) Holdings (LabCorp (R) ) (NYSE: LH) today announced that William B. (Brad) Hayes, Executive Vice President and Chief Financial Officer, is scheduled to speak at the Credit Suisse 2011 Healthcare Conference in

Laboratory Corporation of America(R) Holdings Announces Third Quarter 2011 Results

Strong Revenue Growth Drives EPS of $1.31 and Adjusted EPS Excluding Amortization of $1.61 BURLINGTON, N.C., Oct 20, 2011 (BUSINESS WIRE) -- Laboratory Corporation of America (R) Holdings (LabCorp (R) ) (NYSE: LH) today announced results for the quarter ended September 30, 2011.

LabCorp Extends Tender Offer for All Outstanding Shares of Orchid Cellmark Inc.

BURLINGTON, N.C., Oct 10, 2011 (BUSINESS WIRE) -- Laboratory Corporation of America(R) Holdings (NYSE: LH) today announced that LabCorp is extending until 5:00 p.m., New York City time, on November 4, 2011 LabCorp's previously announced cash tender offer for all outstanding shares of the common

Conversion Right Triggered for LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021

BURLINGTON, N.C., Oct 06, 2011 (BUSINESS WIRE) -- Laboratory Corporation of America (R) Holdings (LabCorp (R) ) (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below.

LabCorp To Offer a New Companion Diagnostic for Non-Small Cell Lung Cancer

BURLINGTON, N.C., Oct 03, 2011 (BUSINESS WIRE) -- Laboratory Corporation of America (R) Holdings (LabCorp (R) ) (NYSE: LH) announced today the nationwide availability of a new FDA-approved companion diagnostic for lung cancer patients. The drug XALKORI (R) , available from Pfizer, and Abbott

LabCorp's Zero Coupon Convertible Subordinated Notes Due 2021 to Accrue Contingent Interest

BURLINGTON, N.C., Sep 13, 2011 (BUSINESS WIRE) -- Laboratory Corporation of America (R) Holdings (LabCorp (R) ) (NYSE: LH) announced today that for the period of September 12, 2011 to March 11, 2012, its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) will, subject to the

LabCorp to Offer a New Companion Diagnostic for Melanoma

BURLINGTON, N.C., Sep 12, 2011 (BUSINESS WIRE) -- Laboratory Corporation of America (R) Holdings (LabCorp (R) ) (NYSE: LH) announced today the nationwide availability of a new FDA-approved diagnostic for melanoma patients. The drug Zelboraf TM and the cobas(R) 4800 BRAF V600 Mutation Test companion